Similarly, recent studies have demonstrated that the therapeutic effects of MSCs are indicated by the PTX-3 level in various in vivo models (e.g., wound healing, ischemic brain injury, and acute lung injury) [45,46,47]. This evidence concerns the gene PTX3 and injury.